67 studies found for:    Open Studies | "Nasopharyngeal Neoplasms"
Show Display Options
Rank Status Study
21 Recruiting TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC
Condition: EBV-positive Nasopharyngeal Carcinoma
Intervention: Genetic: DNR.NPC-specific T cells
22 Recruiting Dietary Nitrate on Plasma Nitrate Levels for Nasopharyngeal Carcinoma Patients
Condition: Nasopharyngeal Carcinoma
Interventions: Dietary Supplement: nitrate supplementation;   Dietary Supplement: Placebo
23 Unknown  GC Regimen Chemotherapy Plus CIK Cells for Metastatic Nasopharyngeal Carcinoma
Condition: Stage IV Nasopharyngeal Carcinoma
Interventions: Drug: GC chemotherapy plus CIK cells (Gemcitabine, Cisplatin, Autologous CIK cells);   Drug: GC chemotherapy (Gemcitabine, Cisplatin)
24 Recruiting Study Evaluating Two Loading Regimens of Sunitinib Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)
Condition: Nasopharyngeal Carcinoma
Interventions: Drug: 12.5mg sunitinib with Cisplatin and Gemcitabine;   Drug: 25mg Sunitinib alternating with Cisplatin and Gemcitabine
25 Unknown  Molecular Mechanism of Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Intervention:
26 Recruiting Phase II Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC)
Conditions: Stage II Lymphoepithelioma of the Nasopharynx;   Stage II Squamous Cell Carcinoma of the Nasopharynx;   Stage III Lymphoepithelioma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Lymphoepithelioma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx
Interventions: Drug: docetaxel;   Drug: cisplatin;   Drug: carboplatin;   Drug: fluorouracil;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
27 Unknown  Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer
Condition: Advanced Nasopharyngeal Cancer
Interventions: Drug: Nimotuzumab;   Drug: placebo plus chemoradiotherapy
28 Not yet recruiting Induction Chemotherapy With GP Versus TPF in the Treatment of Advanced Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Interventions: Drug: A combination of Gemcitabine and cisplatin;   Drug: A combination of Docetaxel, cisplatin and 5-Fluorouracil
29 Recruiting OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive Chemoradiotherapy
Condition: Nasopharyngeal Carcinoma
Intervention: Drug: OPB-51602
30 Recruiting PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer
Interventions: Drug: PI3K inhibitor BKM120;   Biological: cetuximab;   Other: laboratory biomarker analysis;   Other: questionnaire administration
31 Unknown  Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma (NPC)
Condition: Nasopharyngeal Carcinoma
Interventions: Drug: docetaxel, cisplatin, fluorouracil;   Radiation: 3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)
32 Not yet recruiting The Value of Single-cycle TPF Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Interventions: Drug: One cycle TPF induction chemotherapy for NPC;   Drug: Three cycles TPF induction chemotherapy for NPC
33 Recruiting Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer
Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer
Interventions: Biological: oncolytic measles virus encoding thyroidal sodium iodide symporter;   Other: laboratory biomarker analysis
34 Unknown  Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)
Conditions: Recurrent Nasopharyngeal Carcinoma;   Metastatic Nasopharyngeal Carcinoma
Intervention: Drug: Famitinib
35 Unknown  Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Interventions: Drug: Icotinib;   Radiation: intensity-modulated radiotherapy;   Drug: Paclitaxel and Cisplatin;   Other: Quality of life;   Genetic: Epidermal growth factor receptor status
36 Recruiting New Approach of Assessing Drug Response for Treatment of Nasopharyngeal Cancer
Condition: Advanced Nasopharyngeal Carcinoma
Intervention: Drug: Chemotherapy
37 Not yet recruiting Weekly Cisplatin or Nedaplatin Concurrent With Intensity-modulated Radiation Therapy in Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Interventions: Drug: Nedaplatin;   Drug: Cisplatin
38 Recruiting Chemotherapy Combined With Radiotherapy vs Chemotherapy Alone for Distant Metastatic Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Intervention: Radiation: Loco-regional Radiotherapy
39 Recruiting Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Interventions: Drug: Nedaplatin;   Drug: Cisplatin
40 Recruiting Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Intervention: Drug: Nimotuzumab Injection

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years